Skip to main content

Perrigo Company Value Stock - Dividend - Research Selection

Perrigo

ISIN: IE00BGH1M568 , WKN: A1XAEY

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Perrigo Company plc, a healthcare company, manufactures and supplies over-the-counter (OTC) healthcare products, infant formulas, branded OTC products, and generic pharmaceutical products worldwide. The company operates through Consumer Healthcare Americas, Consumer Healthcare International, and Prescription Pharmaceuticals segments. It offers OTC products in cough, cold, allergy, sinus, analgesic, gastrointestinal, smoking cessation, infant formula and food, animal health, diagnostic, lifestyle, personal care and derma-therapeutics, natural health and vitamins, and anti-parasite categories. The company also develops, manufactures, and markets a portfolio of generic prescription drugs, such as creams, ointments, lotions, gels, shampoos, foams, suppositories, sprays, liquids, suspensions, solutions, powders, controlled substances, injectables, hormones, oral solid dosage forms, and oral liquid formulations. In addition, it offers contract manufacturing services. The company offers its products through retail drug, supermarket, and mass merchandise chains; hospitals; pharmacies; wholesalers; drug and grocery stores; and para pharmacies, as well as through a network of pharmacy sales force in North America, Europe, Australia, Israel, and China. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Perrigo Company plc 2026 Q1 - Results - Earnings Call Presentation

2026-05-06
2026-05-06. The following slide deck was published by Perrigo Company plc in conjunction with their 2026 Q1 earnings call.

Perrigo Company plc Reports Earnings Results for the First Quarter Ended March 28, 2026

2026-05-06
Perrigo Company plc reported earnings results for the first quarter ended March 28, 2026. For the first quarter, the company reported sales was USD 969.2 million compared to USD 1,043.9 million a year...

Perrigo: Q1 Earnings Snapshot

2026-05-06
DUBLIN — DUBLIN — Perrigo Co. on Wednesday reported a loss of $398.6 million in its first quarter. The Dublin-based company said it had a loss of $2.87 per share. Earnings, adjusted for...

Perrigo Reports First Quarter 2026 Financial Results From Continuing Operations

2026-05-06
Mitigating category headwinds with market share gains through implementation of Three‑S plan.Specialty Care segment achieved net sales and segment operating income growth, led by continued momentum...

Perrigo Completes Divestiture of Dermacosmetics Business

2026-04-30
Perrigo Company plc (NYSE: PRGO) ("Perrigo" or the "Company"), a leading global provider of consumer health products, today announced that it has completed the previously announced sale of its branded Dermacosmetics business to Karo Healthcare ("Karo") for total consideration of up to €332.6 million. The transaction consists of €305.6 million in upfront cash, including €5.6 million in net working capital adjustments, and up to an additional €27.0 million contingent on the achievement of net sale

ICU Medical (ICUI) Reports Next Week: Wall Street Expects Earnings Growth

2026-04-30
ICU Medical (ICUI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Perrigo (PRGO) to Report a Decline in Earnings: What to Look Out for

2026-04-29
Perrigo (PRGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Perrigo Announces Quarterly Dividend

2026-04-29
Perrigo Company plc (NYSE: PRGO), a leading global provider of consumer products, today announced that its Board of Directors has approved a quarterly dividend of $0.29 per share, or $1.16 per share on an annualized basis. The cash dividend is payable on June 16, 2026, to shareholders of record on May 29, 2026.

3 Healthcare Stocks Paying the Highest Dividends in the Sector Right Now

2026-04-29
The highest-yielding healthcare stocks come with some side effects.

Perrigo: Positioning Through A Thesis Reset

2026-04-28
Perrigo was our biggest loser in 2025 at -46%, and the pain continued into Q1. Read more here.